We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Investment in Prescription to Over the Counter Switch Incubators Aims to Support Patient Self Care


Want a FREE PDF version of this product news?

Complete the form below and we will email you a PDF version of "Investment in Prescription to Over the Counter Switch Incubators Aims to Support Patient Self Care"

Listen with
Speechify
0:00
Register for FREE to listen to this article
Thank you. Listen to this article using the player above.
Read time:
 

BioCity has announced investment in Maxwellia’s prescription (Rx) to
Over the Counter (OTC) switch incubator. The creation of new OTC products
potentially enables quicker therapeutic outcomes for many, who may not
previously have sought treatment. For the NHS, the shift towards self-care also
supports the wider public health issues by freeing-up GP's time. Maxwellia’s
approach converts prescription drugs into versions that can be purchased
without prescription from pharmacies and supermarkets; a process known as
‘switching’.

BioCity investment analyst, Dr. Imelda Juniarsih said "By providing
consumers with quicker, wider and more convenient access to medicines and
reducing the burden felt by the NHS, Maxwellia could support and accelerate the
move towards self-care and provide early intervention opportunities for some
long-term conditions in the UK.”

Advertisement